Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

Nanion Technologies GmbH. (1/22/15). "Press Release: Nanion TWIns with Stem Cells as New Facilities Are Opened in Japan and USA". Tokyo & Livingstone, NJ.

Region Region Tokyo
  Country Japan
Organisations Organisation Nanion Technologies Research Lab Tokyo (at TWIns)
  Today European Bioplastics (EUBP)
  Organisation 2 Tokyo Women’s Medical University – Waseda University Joint Institution for Advanced Biomedical Sciences (TWIns)
  Group Tokyo Women’s Medical University (TWMU)
Products Product SyncroPatch 384/768PE automated patch clamp system
  Product 2 iPSC technology (induced pluripotent stem cell technology)
Index term Index term Nanion–Tokyo Women’s Medical Univ: patch clamp system, 201501– collab optimising performance of iPS cells an Nanion systems
Person Person Haedo, Rodolfo (Nanion Technologies 201410 VP Nanion Technologies Inc)

Nanion is expanding on two continents as new state-of-the-art research and demonstration facilities are opened in Tokyo, Japan and Livingston, NJ, USA. The new facilities provide the opportunity for customers to see Nanion’s entire product portfolio in action, from the Port-a-Patch to the SyncroPatch 384/768PE.

Nanion Technologies, an innovative German-based company providing high quality devices for ion channel research and drug discovery, recently expanded into new premises in both Japan and USA. Nanion Technologies Inc. opened in 2008 and due to expansion of personnel and devices it has now moved to larger premises in Livingston, NJ, with fully equipped laboratory facilities for validation experiments and demonstrations of the entire Nanion product range. Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:

Rodolfo Haedo, VP of Nanion Technologies Inc. says about the move:
”We are very excited to move to these new, larger and more modern premises. We have had huge interest in the SyncroPatch 384/768PE high throughput screening tool since its launch in 2013 and have an ever-increasing installed base of the instruments in the US. The SyncroPatch 384PE has been so well received by customers so far and we see a bright future for sales this year, as well as for our other Nanion instrumentation in the US. These new premises will give us the opportunity to exhibit our complete product range to its full potential”.

In Tokyo, Japan, Nanion has opened a new research laboratory within the Tokyo Women’s Medical University - Waseda University Joint Institution for Advanced Biomedical Sciences (TWIns) . TWIns is a leading facility for induced pluripotent stem (iPS) cell research where Nanion has established a close collaboration with the Tokyo Women’s Medical University (TWMU) to combine the use of iPS cells on Nanion’s devices. Customers will be able to visit the facility to see the Nanion platforms in action with cells and receive high-quality support including iPS cardiomyocytes and neurons.

Nanion Japan’s expert electrophysiologist and general manager, Atsushi Ohtsuki, says about the new premises:
“TWIns is a recognized institute for stem cell research with an excellent reputation. Our collaboration with TWMU will enable optimal performance of iPS cells on Nanion’s platform. We will have the full range of Nanion’s products available for scientific support or demonstrations in this new state-of-the-art facility in the heart of Tokyo, and look forward to welcoming both potential and existing customers to visit us here.”

About Nanion Technologies

Nanion Technologies is a one-stop-shop for ion channel drug discovery and screening technologies as well as sophisticated research instrumentation. Nanion was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and successfully established four generations of automated patch clamp instruments for sophisticated and high throughput applications in ion channel research and drug discovery (Port-a-Patch, Patchliner and SyncroPatch product families). Further product lines are for cardiotoxicity screening (CardioExcyte 96), for parallel bilayer recordings (Orbit 16), and for parallel membrane transporter protein recordings (SURFE2R). Recently, Nanion’s management team was nominated for the Federal President’s Award for Technology and Innovation (Deutscher Zufunftspreis 2014).

Record changed: 2019-06-09


Picture [iito] – Putting Information into Context 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top